Sophia Genetics SA
SOPH
View Detailed Chart
4.780USD
+0.170+3.69%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
324.31MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.69%
5 Days
+1.27%
1 Month
+5.29%
6 Months
+57.24%
Year to Date
+55.70%
1 Year
+46.63%
View Detailed Chart
TradingKey Stock Score of Sophia Genetics SA
Currency: USD Updated: 2025-12-22Key Insights
Sophia Genetics SA's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 173/482 in the Software & IT Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sophia Genetics SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
7.333
Target Price
+50.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sophia Genetics SA Highlights
StrengthsRisks
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 37.03% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.17M.
Undervalued
The company’s latest PE is -4.28, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.89M shares, decreasing 24.99% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 30.80K shares of this stock.
Sophia Genetics SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sophia Genetics SA Info
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Ticker SymbolSOPH
CompanySophia Genetics SA
CEOCamblong (Jurgi)
Websitehttps://www.sophiagenetics.com/
FAQs
What is the current price of Sophia Genetics SA (SOPH)?
The current price of Sophia Genetics SA (SOPH) is 4.780.
What is the symbol of Sophia Genetics SA?
The ticker symbol of Sophia Genetics SA is SOPH.
What is the 52-week high of Sophia Genetics SA?
The 52-week high of Sophia Genetics SA is 5.300.
What is the 52-week low of Sophia Genetics SA?
The 52-week low of Sophia Genetics SA is 2.580.
What is the market capitalization of Sophia Genetics SA?
The market capitalization of Sophia Genetics SA is 324.31M.
What is the net income of Sophia Genetics SA?
The net income of Sophia Genetics SA is -62.49M.
Is Sophia Genetics SA (SOPH) currently rated as Buy, Hold, or Sell?
According to analysts, Sophia Genetics SA (SOPH) has an overall rating of --, with a price target of 7.333.
What is the Earnings Per Share (EPS TTM) of Sophia Genetics SA (SOPH)?
The Earnings Per Share (EPS TTM) of Sophia Genetics SA (SOPH) is -1.116.
Related Instruments
+0.88%
+0.85%
-0.21%
+0.41%
+0.80%
+3.33%
+0.59%
+0.31%
-1.23%
+0.78%
+0.36%
+0.60%
+1.76%
+1.70%
+0.06%
+2.45%
-0.59%
+2.19%
+0.47%
+1.40%Popular Symbols
